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Colorectal cancer is the third most common cancer worldwide and is associated with
significant morbidity and mortality. Current pharmacotherapy options include cytotoxic
chemotherapy, anti-VEGF, and anti-EGFR targeting drugs, but these are limited by
toxic side effects, limited responses and ultimately resistance. Cysteinyl leukotriene
(CysLT) signaling regulates intestinal homeostasis with mounting evidence suggesting
that CysLT signaling also plays a role in the pathogenesis of colorectal cancer. Therefore,
CysLT signaling represents a novel target for this malignancy. This review evaluates
reported links between CysLT signaling and established hallmarks of cancer in addition
to its pharmacological potential as a new therapeutic target.
Keywords: cysteinyl leukotriene, eicosanoid, colorectal cancer, tumorigenesis, hallmarks of cancer, cysteinyl
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INTRODUCTION
Each year, ∼1.4 million new cases of colorectal cancer (CRC) are diagnosed, with almost 700,000
cancer-related deaths, making it the third most common cancer worldwide and the fourth most
common cause of cancer death (Torre et al., 2015). Surgical intervention is the cornerstone of
treatment but adjuvant chemotherapy and targeted therapies play significant roles in improving
survival. Treatment decision is guided by clinical factors (e.g., co-morbid conditions, performance
status) and pathological factors (e.g., KRAS mutation status, microsatellite stability status).
5-fluorouracil-based regimens such as FOLFOX or FOLFIRI form the backbone of cytotoxic
chemotherapy in the treatment of metastatic disease but are limited by chemoresistance and toxic
effects on non-neoplastic healthy tissue (Longley and Johnston, 2005; Fuchs et al., 2007).
Targeted therapies include the anti-angiogenic drug bevacizumab (Avastin R©), a humanized
monoclonal antibody that binds directly to vascular endothelial growth factor A (VEGF-A; Ferrara
et al., 2004). Blocking VEGF inhibits tumor angiogenesis, a pathophysiological process upon which
solid tumors depend for growth, survival, andmetastasis (Folkman, 1971). Other targeted therapies
include anti-epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab,
the major advantage of which is the availability of a validated biomarker that reliably predicts
patient response—patients with activating KRAS mutations have poorer progression-free and
overall survival (Martinelli et al., 2009; Yen et al., 2010). Immune checkpoint inhibition is emerging
as a promising treatment strategy in microsatellite instability-high (MSI-H) colorectal tumors, a
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phenotype resulting from defective DNA mismatch repair and
accounting for up to 15% of all CRCs (Boland and Goel,
2010; Le et al., 2015). Pembrolizumab, an anti-programmed
cell death protein 1 (anti-PD-1) antibody potentiates T-cell
immune responses, circumventing tumor immune evasion, and
significantly prolonging progression-free survival in patients
with MSI-H tumors (McDermott and Atkins, 2013; Le et al.,
2015). Numerous other immunotherapies are currently being
evaluated in clinical trials in combination with chemotherapy
regimens and/or targeted therapies.
While CRC survival rates are improving, there is a need for
more effective therapies as the survival benefit associated with
targeted therapies is only∼4–5 months (McCormack and Keam,
2008; Bokemeyer et al., 2012). Many novel strategies are currently
under investigation, one of which is to target cysteinyl leukotriene
(CysLT) signaling. The focus of this mini-review is to evaluate the
link between CysLTs and the hallmarks of cancer.
CYSTEINYL LEUKOTRIENES AND THEIR
RECEPTORS
Cysteinyl leukotrienes (CysLTs) are a subfamily of eicosanoids,
lipophilic signaling molecules that regulate both acute and
chronic inflammation (Henderson, 1994). These potent bioactive
lipids are rapidly generated de novo from cell membrane-
associated arachidonic acid (AA), an essential polyunsaturated
fatty acid in response to cell activation (Clark et al., 1991). Once
mobilized to the cytosol, AA is metabolized by 5-lipoxygenase
(5-LOX) in conjunction with 5-lipoxygenase-activating protein
(FLAP) to yield leukotriene A4 (LTA4), which undergoes further
metabolism to form leukotrienes B4 (LTB4) and C4 (LTC4)
(Kanaoka and Boyce, 2004). Subsequently LTC4 is exported from
the cell via multi-drug resistance-associated proteins 1 and 4, and
metabolized to LTD4 and LTE4 (Lam et al., 1989). LTC4, LTD4,
and LTE4, referred to collectively as CysLTs, are structurally
similar but exhibit functional diversity (Laidlaw and Boyce,
2012).
The biological actions of CysLTs are mediated via ligation
of the widely distributed G-protein-coupled receptors, CysLT1
and CysLT2 (Figure 1; Peters-Golden et al., 2006). The role of
newly-identified CysLT receptors GPR17 and GPR99 remains
to be established. GPR17 is an orphan P2Y-like receptor with
dual specificity for uracil nucleotides and CysLTs, while GPR99
has been proposed as a potential LTE4-selective CysLT receptor
(Ciana et al., 2006; Kanaoka et al., 2013). Cross-regulation occurs
between CysLT receptors—CysLT2 negatively regulates CysLT1
signaling via receptor heterodimerization and GPR17 has been
reported as a ligand-independent negative regulator of CysLT1
(Lynch et al., 1999; Jiang et al., 2007; Maekawa et al., 2009).
CYSTEINYL LEUKOTRIENES AND THEIR
ROLE IN CANCER
CysLTs play recognized roles in promoting the inflammatory
response, bronchoconstriction and vascular permeability
(Davidson et al., 1987; Lee et al., 2004). CysLTs have also recently
emerged as important regulators of intestinal homeostasis,
with endogenous CysLT production mediating the survival and
proliferation of intestinal epithelial cells (Paruchuri et al., 2006).
Dysregulated CysLT signaling has been implicated in colorectal
adenocarcinomas with increased CysLT1 and decreased CysLT2
levels in patient tumor samples compared with surrounding
normal tissue (Magnusson et al., 2007). Interestingly, unlike the
majority of G-protein coupled receptors, CysLT1 and CysLT2 are
located both at the plasma membrane and the nuclear membrane
(Magnusson et al., 2010). This subcellular receptor localization
is critically important for CRC patient survival - patients with
high nuclear CysLT1 expression have a poorer prognosis than
patients with high cytoplasmic expression (Magnusson et al.,
2010). In contrast, patients with high nuclear CysLT2 expression
have a better overall survival expectancy, indicating the existence
of an inverse relationship between nuclear CysLT1 and CysLT2
expression, and suggesting that CysLT2 has a protective role in
CRC (Magnusson et al., 2010).
In vitro data corroborate these findings as malignant intestinal
cell lines Caco-2 and SW480 demonstrate higher CysLT1 but
lower CysLT2 expression levels compared to non-cancerous Int
407 intestinal epithelial cells (Magnusson et al., 2007). CysLT2
signaling also results in terminal differentiation of Caco-2 cells
and growth inhibition (Magnusson et al., 2007). All-trans retinoic
acid (ATRA), an anti-cancer agent promoting cell differentiation,
acts in part by upregulating CysLT2 mRNA expression and LTC4
synthase (Bengtsson et al., 2013).
Interestingly, CysLT1 expression increases CRC tumor
burden in a gender-specific manner in vivo—In the ApcMin/+
mouse model of familial adenomatous polyposis/sporadic CRC,
female mice lacking the CysLT1 gene (Cysltr1
−/− ApcMin/+)
develop significantly less polyps, less systemic inflammation,
and increased regulatory T-cell tumor infiltration, a negative
prognostic factor in CRC, compared to Cysltr1 +/+ ApcMin/+
mice.
Analysis of The Cancer Genome Atlas (TCGA) RNA-
sequencing dataset reveal that GPR17 and GPR99 are expressed
in CRC patient samples, with GPR99 more highly expressed
relative to GPR17 based on FPKM relative expression values.
Kaplan-Meier survival analysis was conducted using a log-rank
test with the “survival” package in R and grouping 41 tumor
samples based on median expression. We found no significant
correlation of either gene with overall survival. While both
receptors have been identified in the colon, further investigation
in a larger cohort of CRC patients is required to confirm these
findings.
CysLTs have multiple roles in many hallmarks of cancer
(Figure 2).
Sustained Proliferative Signaling
CysLTs induce cell proliferation in various cell types including
bone marrow cells, smooth muscle cells, endothelial cells, and
intestinal cells and it is suggested that dysregulated CysLT
signaling contributes to uncontrolled proliferation (Lindgren
et al., 1993; Porreca et al., 1996; Paruchuri and Sjölander, 2003;
Duah et al., 2013). LTD4 induces intestinal cell proliferation
in Int 407 cells via stimulation of the Erk 1/2 pathway and
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FIGURE 1 | Cysteinyl leukotriene receptors: pharmacology, distribution, function and signaling pathways. Upon binding of ligand to the CysLT receptor
various downstream signaling pathways are activated. CysLT1 induces PI3K-Akt signaling, resulting in β-catenin nuclear translocation and activation of target genes
including cyclin D1, COX-2, and c-Myc (Savari et al., 2014). Akt/PKB activates IKK complex with subsequent degradation of IκB protein leading the NF-kB
translocation and activation (Madrid et al., 2001). CysLT1, CysLT2, and GPR17 signaling can also activate phospholipase C (PLC) and Ras-Raf-MEK-ERK pathway
(Thompson et al., 2008; Hennen et al., 2013; Savari et al., 2014). This lead to nuclear translocation of Erk 1/2 resulting in activation of genes involved in proliferation,
migration, survival. Alternatively, CysLT receptor ligation can activate PKC and the transcription factor cAMP response element-binding protein (CREB; Savari et al.,
2014). Crosstalk occurs between CysLT and EGF signaling pathways – EGF signaling also activates Rac and the Ras-Raf-MEK-ERK pathway (Magi et al., 2014). EGF
signaling induces production of 5-LOX, resulting in leukotriene synthesis and consequential potentiation of CysLT receptor signaling, while LOX/CysLT1 also regulate
EGF-induced migration (Magi et al., 2014). PLC, phospholipase C; PKC, protein kinase C; p90RSK, p90 ribosomal S6 kinase; CREB, cAMP response element
binding; NF-κB, nuclear factor kappa b; IKK, IkB kinase; TCF/LEF, T-cell factor/lymphoid enhancer factor; β-cat, β-catenin; APC adenomatous polyposis coli; GSK-3β
glycogen synthase kinase-3 beta; PKB protein kinase B; PI3K, phosphoinositide 3-kinase; 5-LOX, 5-lipoxygenase; EGF, epidermal growth factor; EGFR, epidermal
growth factor receptor.
subsequent activation of p90 ribosomal S6 kinase (p90RSK;
Paruchuri et al., 2002). LTD4 also reduces G0/G1 and increases
S+G2/M phases of Int 407 cell cycle, further supporting a role
in intestinal cell proliferation. CysLT1 signaling via the GSK-
3β/β-catenin pathway increases transcription of target genes
COX-2, c-Myc and Cyclin D1, well-known modulators of cell
proliferation (Savari et al., 2014). The β-catenin pathway is
negatively regulated by the APC tumor-suppressor protein and is
critical in colorectal carcinogenesis—over 80% of sporadic CRCs
carry a somatic mutation of the APC gene, while a germline
mutation carries an almost 100% lifetime risk of CRC (Kinzler
and Vogelstein, 1996; Jasperson et al., 2010).
The proliferative effects of CysLTs in the intestine depend on
the receptor subtype. CysLT1 signaling induces proliferation of
Int 407 epithelial cells in an autocrine manner, whereas CysLT2
signaling promotes terminal cell differentiation of Caco-2 cells,
inhibiting growth (Paruchuri et al., 2002;Magnusson et al., 2007).
CysLT2 expression is significantly higher during the quiescent
G0 phase of the intestinal cell cycle compared to actively
proliferating phases (Magnusson et al., 2007). In HCT-116
colorectal xenograft mouse models, CysLT1 antagonists reduce
proliferation as determined by Ki-67 levels and significantly
reduce tumor size (Savari et al., 2013). The role of non-classical
CysLT receptors in cell proliferation is unknown—GPR17+ cells
demonstrate proliferative activity in the central nervous system
but have not been investigated in a CRC context (Ceruti et al.,
2009).
Migration, Invasion
Cell migration, facilitated by the epithelial-mesenchymal
transition (EMT) process, is essential for tumor invasion,
angiogenesis, and metastasis. CysLT1 signaling stimulates
the migration of Int 407 intestinal epithelial cells via a
phosphatidylinositol 3-kinase and Rac-dependent mechanism
(Paruchuri et al., 2005). LTD4 also stimulates HCT-116 colon
cancer cell migration and decreases expression of adhesion
molecule E-cadherin, a key mediator of the EMT process
(Hirohashi, 1998; Salim et al., 2014).
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FIGURE 2 | Cysteinyl leukotriene signaling modulates many of the hallmarks of cancer in colorectal cancer. Mounting evidence indicates CysLTs play an
important role in the tumorigenesis of colorectal cancer. CysLT signaling modifies 7 out of the 10 Hanahan and Weinberg hallmarks of cancer (Hanahan and Weinberg,
2011). CysLTs sustain proliferative signaling, activate migration and invasion, induce angiogenesis, contribute to genome instability and mutation, deregulate cellular
energetics, and resist cell death. No evidence to date supports a role for CysLT in enabling replicative immortality, evading immune destruction or evading growth
suppressors. PI3K, phosphoinositide 3-kinase; EGF, epidermal growth factor; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor kappa b; TNFα, tumor
necrosis factor alpha; CREB, cAMP response element binding; NOX4, NADPH oxidase 4; ROS, reactive oxygen species; MGST2, microsomal glutathione
S-transferase 2; EC, endothelial cell.
Crosstalk between EGFR signaling and CysLT1 signaling
is essential for epithelial cancer migration and invasion—the
LOX/LTC4/CysLT1 signaling pathway regulates EGF-induced
cell migration via Rac1 activation in A431 human epidermoid
carcinoma cells (Magi et al., 2014). Conversely CysLT2 signaling
has been shown to reduce cell migration in MCF-7 breast
cancer cell lines, further substantiating many reports that CysLT
receptors have opposing effects (Jiang et al., 2007; Magnusson
et al., 2007, 2011a; Bengtsson et al., 2013). GPR17 signaling
stimulates migration in oligodendrocytes and cardiac stromal
cells but its effect on intestinal cells have not been investigated
(Coppi et al., 2013; Cosentino et al., 2014).
Angiogenesis
In order to sustain growth, a tumor must obtain a blood
supply by tilting the balance of angiogenic mediators in favor
of angiogenesis (Bergers and Benjamin, 2003). CysLT1 signaling
activates production of the pro-angiogenic mediator VEGF-A in
vitro, while CysLT antagonists modulate vascular permeability
and reduce VEGF levels in murine models of allergic asthma
and in asthmatic patients (Kanazawa et al., 2004; Lee et al., 2004;
Poulin et al., 2011).
CysLT1 and CysLT2 receptors are both expressed in vascular
endothelial cells (ECs) and vascular smooth muscle cells, either
constitutively or inducibly—although CysLT2 is the dominant
receptor type (Gronert et al., 2001; Sjöström et al., 2003;
Kaetsu et al., 2007). Transgenic mice overexpressing endothelial
CysLT2 exhibit vascular hyperpermeability and upregulate
ICAM-1 and VCAM-1 expression, adhesion molecules which
regulate angiogenesis (Jiang et al., 2008; Ni et al., 2014).
Conflicting reports surround the regulation of EC function by
CysLTs—CysLT stimulation has been shown to increase human
umbilical vein endothelial cell proliferation in vitro (Duah
et al., 2013). Yuan et al. (2009) demonstrated no proliferative
effect in EA.hy926 macrovascular endothelial cells upon CysLT
stimulation, solely induction of endothelial cell migration. In
vivo, CysLTs significantly enhance microvessel growth in rat
thoracic aortic ring and chick chorioallantoic membrane assays
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in a dose-dependent manner, an effect abrogated by both CysLT1
and CysLT2 antagonists (Tsopanoglou et al., 1994; Xu et al.,
2010).
Furthermore, GPR99 and its ligand α-ketoglutarate
upregulate EC proliferation and promote vessel sprouting
and neovascularization using in vivo models of retinal
angiogenesis (Sirinyan et al., 2007). GPR99 also mediates
cutaneous vascular permeability in mouse respiratory models
(Bankova et al., 2016).
Oxidative DNA Damage, Genome
Instability, and Mutation
DNA damage and genomic instability is a primary driver of
carcinogenesis (Shen, 2011). Recent evidence highlights the
role of LTC4 in promoting oxidative DNA damage, which if
not sufficiently repaired may contribute to genomic instability
and increased mutation rates (Dvash et al., 2015). A previously
unrecognized microsomal glutathione-S-transferase 2 (MGST2)-
LTC4 signaling pathway elicits nuclear translocation of NADPH
oxidase 4 (NOX4) and generation of reactive oxygen species
(ROS) when triggered by endoplasmic reticulum (ER) stress
and chemotherapy (Dvash et al., 2015). Activation of this
pathway upregulates MGST2, CysLT production enzymes and
CysLT1 and CysLT2 expression in human amniotic WISH
epithelial cells. LTC4 antagonists reduce NOX4 levels, inhibit
ROS accumulation and significantly attenuate nuclear DNA
damage induced by the chemotherapeutic agent doxorubicin
(Dvash et al., 2015). Therefore, LTC4 antagonism may have
potential in combination with chemotherapy to reduce
toxicities.
Cancer cells often exhibit ER stress due to high proliferation
rates (Wang et al., 2010). Therefore, while this pathway may
not be responsible for the initiation of tumorigenesis, it may
contribute to tumor progression via an ER-stress triggered
mechanism of leukotriene production.
Resisting Apoptosis
CysLT signalingmay induce intestinal cell resistance to apoptosis,
as evidenced by the increase in cell survival of Int 407 intestinal
cells exposed to LTD4 (Ohd et al., 2000). CysLT1 signaling
increases COX-2 expression and subsequent expression of the
anti-apoptotic protein Bcl-2 by activating the MEK/Erk signaling
pathway in the Caco-2 cell line (Wikström et al., 2003).
LTD4 promotes mitochondrial translocation of β-catenin in Int
407 intestinal cells where it induces Bcl-2 expression, thereby
protecting cells from apoptosis and enhancing cell survival
(Mezhybovska et al., 2006). The mechanism by which the CysLT1
signaling exerts this pro-survival effect has been attributed to
cAMP response element-binding protein (CREB), a transcription
factor implicated in the pathophysiology of a number of cancers
(Paruchuri and Sjölander, 2003; Sakamoto and Frank, 2009).
While CysLT1 signaling can inhibit intestinal cell apoptosis,
CysLT2 signaling appears to have no effect on the levels of
apoptosis in a MCF-7 breast cancer cell line (Magnusson et al.,
2011b).
Deregulating Cellular Energetics
The glycolytic metabolic switch adapted by tumor cells is
necessary to support the demands of rapid cell proliferation, and
is critically mediated by the “master regulator” c-Myc oncogene
(Miller et al., 2012). CysLT1 signaling activates transcription of
c-Myc via induction of β-catenin nuclear translocation in Int 407
intestinal epithelial cells (He et al., 1998; Ohd et al., 2000). CysLT1
activation also induces the PI3K-Akt signaling pathway in Int
407 cells, constitutive activation of which stimulates glycolysis
(Elstrom et al., 2004;Mezhybovska et al., 2005). LTD4 stimulation
increases metabolic activity in both non-transformed Int 407
epithelial cells and Caco-2 colon cancer cells with observed
increases in ATP/ADP ratios. LTD4 also triggers significant
increases in mitochondrial gene activity, changes in which have
been identified in primary tumors of CRC patients (Polyak et al.,
1998; Mezhybovska et al., 2009).
Interestingly, a key citric acid cycle intermediate
α -ketoglutarate has been identified as a ligand GPR99 (He
et al., 2004). α-ketoglutarate is also a substrate for prolyl
hydroxylases which regulate hypoxia inducible factor 1α, a key
player in the reprogramming of cancer metabolism (MacKenzie
et al., 2007).
Tumor-Promoting Inflammation
Chronic inflammation is a risk factor for the development
of cancer, as illustrated in inflammatory bowel disease (IBD)
patients (Bernstein et al., 2001). IBD patients exhibit a 3 to seven-
fold higher expression of leukotriene pathway enzymes—it is
currently unknown if this correlates with an increased risk of
cancer development (Jupp et al., 2007). LTD4 antagonists reduce
colonic inflammation in a rat model of acute colitis induced by
intracolonic administration of trinitrobenzene sulfonic acid and
may have potential in the prevention of inflammation-associated
CRC (Nishikawa et al., 1995).
CysLTs act as leukocyte chemoattractants—CysLT1 mediates
Th17 cell migration, accumulation of which correlates with
the progression of inflammation-associated cancer (Kim and
Lee, 2015). Tumor-associated macrophages (TAMs) within the
tumor microenvironment also secrete high levels of LTD4 which
may further promote immune cell infiltration (Zhang, 2013).
Tumor necrosis factor-α (TNF-α), a pro-inflammatory cytokine
involved in the initiation and propagation of CRC, upregulates 5-
LOX, LTC4 synthase and CysLT1 while downregulating CysLT2
expression in SW-480, HCT-116, HT-29, and Caco-2 colon
cancer cells (Yudina et al., 2008). CysLTs also activate NF-κB,
a transcriptional regulator of numerous inflammatory genes,
constitutively active in up to 80% of colorectal tumors (Lind et al.,
2001; Kawano et al., 2003; Hashimoto et al., 2009).
GPR17 negatively regulates CysLT1-mediated immune cell
accumulation in the lungs, while GPR99 is proposed to
elicit a pro-inflammatory response upon binding of LTE4,
the predominant CysLT in inflamed tissue (Kanaoka et al.,
2013; Akiko Maekawa et al., 2016). Autocrine CysLT1 signaling
loops could allow intestinal epithelial cells to maintain chronic
inflammation, thereby increasing the risk of inflammation-
associated CRC (Paruchuri et al., 2006).
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PHARMACOLOGICAL POTENTIAL OF
CYSLT SIGNALING MODULATORS
Overall, targeting CysLT signaling is a promising option for anti-
cancer therapy due to its effects on multiple oncogenic pathways
described above (Figure 2). Commercially available anti-
asthmatic drugs which target the CysLT1, have demonstrated
notable in vivo potential as anti-cancer agents. Montelukast, a
CysLT1-selective antagonist significantly reduces tumor volume
in a HCT-116 CRC-specific murine xenograft model, via a
combination of anti-proliferative and pro-apoptotic effects
(Savari et al., 2013). CysLT1 antagonism also exhibits an anti-
angiogenic effect, with reduced blood vessel formation and
VEGF expression levels in colorectal tumors (Savari et al., 2013).
Furthermore, pre-treatment of HCT-116 cells with montelukast
prior to inoculation completely inhibited tumor initiation in
BALB/c nu/nu mice. Montelukast also has antagonistic actions
at GPR17—it is unknown if this receptor is important for the
drug’s anti-neoplastic effect (Ciana et al., 2006). Pranlukast
significantly attenuates chemotherapy-triggered morbidity in
mice via a MGST2-LTC4 pathway, and so may have therapeutic
potential in combination with chemotherapy to reduce toxic side
effects or to reduce the risk of metastases (Dvash et al., 2015).
Furthermore, CysLT1 antagonists potently inhibit the growth of
HCT-116 colon cancer cells, in addition to prostate, urothelial,
and neuroblastoma cancer cell lines (Matsuyama et al., 2007,
2009; Sveinbjörnsson et al., 2008; Savari et al., 2013).
No studies to date have investigated the effects of specific
CysLT2 agonists or antagonists on tumor progression specifically.
In the case of CRC, selective CysLT2 agonism would appear to be
the desired approach, but this needs potent selectivity in order to
avoid negative effects of CysLT1 agonism on the intestine. Due
to cross regulation between CysLT receptors, such a targeting
strategy would need to be approached with caution (Laidlaw and
Boyce, 2012).
Targeting 5-LOX or FLAP to inhibit endogenous production
of CysLTs is an alternative strategy that would circumvent the
increasing number of CysLT isoreceptors. Zileuton, a 5-LOX
inhibitor, prevents colonic polyp formation in an APC1468
mouse model of polyposis and significantly decreases tumor
burden in LoVo and HT29 colon cancer murine xenograft
models (Melstrom et al., 2008; Gounaris et al., 2015). MK-866,
a FLAP inhibitor, reduces proliferation of Caco-2 and HT29
colon cancer cell lines (Ford-Hutchinson, 1991; Cianchi et al.,
2006).
CONCLUSION
These studies highlight the importance of CysLT signaling in
intestinal biology, and its potential role in the tumorigenesis
of colorectal adenocarcinoma. CysLT signaling is linked with
many hallmarks of cancer—cell proliferation and survival, cell
migration, angiogenesis, genomic instability, glycolytic metabolic
switch, and tumor-promoting inflammation. Data largely centers
on CysLT1 and CysLT2 with further investigation necessary to
establish the importance of GPR17 and GPR99 in this context.
Targeting CysLT signaling is a promising pharmacological
strategy, as evidenced by the numerous CysLT antagonists which
have anti-tumor efficacy in in vitro and in vivo CRC models.
In particular, blockade of LTC4 has recently emerged as a
promising new therapeutic opportunity in limiting toxicity to
current chemotherapy drugs. A notable advantage of many
CysLT receptor antagonists is their favorable safety profile. CysLT
signaling modulators may have potential to synergize with other
targeted therapies to benefit survival rates. In summary, CysLT
signaling is gaining increasing recognition as a mediator of
colorectal tumorigenesis and pharmacological manipulation of
this signaling pathway represents an exciting opportunity that
merits further translational research work.
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